JNJ-Super company, Super stock! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : JNJ-Super company, Super stock!

JNJ 188.87

-0.1%

Oct 31 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Lance Bredvold who wrote (477)	1/20/2004 4:23:02 PM
From: Ausdauer	of 552

Lance, thanks for the minutes. From my perspective the fall in the DES cost is needed. US hospitals are losing money on their use as they are not fully reimbursed in many cases. If more than one stent is used the loss is even more substantial. The entry of other competitive stents will segment the market, but as costs decrease overall DES use will increase. JNJ also has had difficulty supplying a full range of stent lengths and sizes which is frustrating to physicians. In this sense they have opened the door to competitors. Part of this was FDA dragging their feet early on. BSX and others will market their stents as equivalent to JNJ and this has worked in Europe. There should be head-to-head comparative data coming out in the not-to-distant future which may help to establish a brand preference. Regarding the analyst comments, Morgan Stanley upgraded one of my portfolio holdings about 1 1/2 weeks ago and the next day they had the audacity to downgrade the same stock. This blatant tactic of encouraging day-to-day oscillations in stock price is reprehensible. I guess Morgan Stanley is resorting to day trading as a new product line. Aus

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next